Document:

Exhibit
4.11

 

Description
of the Registrant’s Securities Registered Pursuant

 to Section 12 of the Securities Exchange Act of 1934

 

Sigma
Labs, Inc. (“Sigma,” “we,” “our,” and “us”) has two classes of securities
registered under Section 12 of the Securities Exchange Act of 1934, as amended: (1) our common stock, par value $0.001 per
share (the “common stock”), and (2) warrants to purchase common stock at an exercise price of $40.00 per share
(the “Public Warrants”).

 

The
following description of our common stock, and preferred stock is a summary and does not purport to be complete. It is subject
to and qualified in its entirety by reference to (1) our Amended and Restated Articles of Incorporation filed as an Exhibit to
our Form 10-K on April 1, 2019, (2) our Certificate of Correction to Amended and Restated Articles of Incorporation filed as an
Exhibit to our Current Report on Form 8-K on June 1, 2011, (3) our Amended and Restated Bylaws filed as an Exhibit to our Form
10-Q on November 14, 2017, (4) Certificate of Designations of Rights Preferences and Privileges of our Series D Convertible Preferred
Stock filed as an Exhibit to our Current Report on Form 8-K filed January 30, 2020, and (5) Certificate of Designations of Rights
Preferences and Privileges of our Series E Convertible Preferred Stock filed as an Exhibit to our Current Report on Form 8-K on
January 30, 2020, each of which is filed as an exhibit to our Annual Report on Form 10-K of which this Exhibit 4.11 is a part.
We encourage you to read the Certificate of Incorporation, the Bylaws, and the Certificates of Designations, as well as the applicable
provisions of the Nevada Revised Statutes (the “NRS”), for additional information.

 

Authorized
Capital Stock

 

We
are presently authorized to issue 2,250,000 shares of common stock, $0.001 par value per share, of which 1,627,182 shares were
outstanding as of March 20, 2020. We are presently authorized to issue 10,000,000 shares of $0.001 par value preferred stock,
of which 1,610,000 shares have been designated “Series A Preferred Stock,” 1,000 shares have been designated “Series
B Convertible Preferred Stock,” 1,500 shares have been designated “Series C Convertible Preferred Stock,” 7,796
shares have been designated as “Series D Convertible Stock” and 500 shares have been designated as “Series E
Convertible Stock.” As of the date of this Form 10-K, we had no shares of Series A Preferred Stock, Series B Convertible
Preferred Stock and Series C Convertible Stock issued and outstanding, 880 shares of Series D Convertible Preferred Stock issued
and outstanding and 333.33 shares of Series E Convertible Preferred Stock issued and outstanding.

 

Common
Stock

 

We
have one class of common stock. Holders of our common stock are entitled to one vote per share on all matters to be voted upon
by stockholders and do not have cumulative voting rights in the election of directors. Holders of shares of common stock are entitled
to receive on a pro rata basis such dividends, if any, as may be declared from time to time by our board of directors in its discretion
from funds legally available for that use, subject to any preferential dividend rights of outstanding preferred stock. They are
also entitled to share on a pro rata basis in any distribution to our common stockholders upon our liquidation, dissolution or
winding up, subject to the prior rights of any outstanding preferred stock. Common stockholders do not have preemptive rights
to subscribe to any additional stock issuances by us, and they do not have the right to require the redemption of their shares
or the conversion of their shares into any other class of our stock. The rights, preferences and privileges of holders of common
stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock that we may
designate and issue in the future.

 

    	 	1	 

    	 

    

 

Public
Warrants

 

The
Public Warrants are exercisable at an exercise price of $40.00 per share, subject to certain adjustments. The Public Warrants
expire on February 21, 2022. Each Public Warrant will have a cashless exercise right in the event that shares of common stock
underlying such Warrants are not covered by an effective registration statement. As of December 31, 2019, we had 162,150 Public
Warrants outstanding.

 

Preferred
Stock

 

Under
our articles of incorporation, our board of directors has the authority, without further action by stockholders, to designate
one or more series of preferred stock and to fix the voting powers, designations, preferences, limitations, restrictions and relative
rights granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and
terms of redemption, liquidation preference and sinking fund terms, any or all of which may be preferential to or greater than
the rights of the common stock.

 

Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and
other rights of the holders of common stock.

 

In
connection with our underwritten public offering of equity securities on February 21, 2017, we created a series of Preferred Stock
called “Series A Preferred Stock.” None of such shares were issued in such offering. In our April 6, 2018 private
placement, we issued 1,000 shares of Series B Preferred Stock (“Series B Preferred”), which were convertible into
100,000 shares of common stock. All shares of our Series B Preferred have been converted and 50,000 shares of common stock issued
upon conversion of such shares are currently beneficially owned by an affiliate of a selling stockholder. In our June 26, 2018
public offering of equity securities, we issued 350 shares of Series C Preferred Stock which were initially convertible into 35,000
shares of common stock. Accordingly, as of the date of this Form 10-K, all shares of such preferred stock have been fully converted.
In connection with the private placements occurring on January 27, 2020, we created two new series of Preferred Stock: the Series
D Preferred Stock and the Series E Preferred Stock. As of the date of this Form 10-K, 880 shares of Series D Preferred Stock and
333.33 shares of Series E Preferred Stock are issued and outstanding.

 

Under
the Certificate of Designations for the Series D Preferred Stock, the Series D Preferred Stock has an initial stated value of
$1,000 per share (the “Stated Value”). Dividends accrue at a dividend rate of 9% per annum (subject to increase upon
the occurrence (and during the continuance) of certain triggering events described therein) will accrue and, on a monthly basis,
shall be payable in kind by the increase of the Stated Value of the Series D Preferred Shares by said amount. The holders of the
Series D Preferred Shares will have the right at any time to convert all or a portion of the Series D Preferred Shares (including,
without limitation, accrued and unpaid dividends and make-whole dividends through the third anniversary of the closing date) into
shares of the Company’s Common Stock at the conversion price then in effect, which initially is $10.00 (subject to adjustment
for stock splits, dividends, recapitalizations and similar events and full ratchet price protection). In addition, a holder may
at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price, which
equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume
weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion. Upon
the occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment
defaults, breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set
forth therein, the Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium
to the underlying value of the Series D Preferred Shares being redeemed.

 

    	 	2	 

    	 

    

 

The
Certificate of Designations contains a prohibition on the issuance of any shares of Common Stock upon conversion of the Series
D Preferred Shares in excess of the amount set forth in NASDAQ Listing Rule 5635(d) (20% or more of the outstanding shares of
common stock) until the Company obtains shareholder approval for issuance of shares of Common Stock in excess of such amount.
In the Institutional SPA, the Company has agreed to promptly obtain such shareholder approval and amend its article of incorporation
and/or effect a reverse split in order to have sufficient shares of Common Stock available to allow the holders of the Series
D Preferred Shares to convert in full the Series D Preferred Shares and exercise in full the Institutional Common Warrants.

 

Under
the Certificate of Designations for the Series E Preferred Stock, the Series E Preferred Shares have an initial stated value of
$1,500 per share (the “Stated Value”). Dividends at the initial rate of 9% per annum will accrue and, on a monthly
basis, shall be payable in kind by the increase of the Stated Value of the Series E Preferred Stock by said amount. The holders
of the Series E Preferred Shares have the right at any time to convert all or a portion of the Preferred Shares (including, without
limitation, accrued and unpaid dividends and make-whole dividends through the third anniversary of the closing date) into shares
of the Company’s Common Stock at an initial conversion rate determined by dividing the Conversion Amount by the Conversion
Price ($0.13 above the consolidated closing bid price for the trading day prior to the execution of the Securities Purchase Agreement,
dated January 27, 2020, between and the purchasers referenced therein). The Conversion Amount is the sum of the Stated Value of
the Series E Preferred Shares then being converted plus any other unpaid amounts payable with respect to the Series E Preferred
Shares being converted plus the “Make Whole Amount” (the amount of any dividends that, but for the conversion, would
have accrued at the dividend rate for the period through the third anniversary of the initial issuance date). The Conversion Rate
is also subject to adjustment for stock splits, dividends recapitalizations and similar events.

 

Transfer
Agent

 

The
transfer agent and registrar of our common stock is Issuer Direct Corporation. The address of our transfer agent and registrar
is 1981 Murray Holladay Road, Suite 100 Salt Lake City, Utah 84117, and its telephone number is (801) 272-9294.

 

Anti-Takeover
Effects of Certain Provisions of Our Charter Documents

 

Our
articles of incorporation and bylaws contain provisions that could delay or prevent changes in control or changes in our management
without the consent of our board of directors. These provisions include the following:

 

	 	●	a classified
    board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of
    a majority of our board of directors; 
	 	 	 
	 	●

	no cumulative voting
    in the election of directors, which limits the ability of minority stockholders to elect director candidates;

 

    	 	3	 

    	 

    

 

	 	●

	the exclusive right
    of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the
    resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of
    directors; 
	 	 	 
	 	●

	the ability of our
    board of directors to authorize the issuance of additional shares of preferred stock and to determine the terms of those shares,
    including preferences and voting rights, without stockholder approval, which could adversely affect the rights of our common
    stockholders or be used to deter a possible acquisition of our company; 
	 	 	 
	 	●

	the ability of our
    board of directors to alter our bylaws without obtaining stockholder approval; 
	 	 	 
	 	●

	the required approval
    of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal
    our bylaws or repeal the provisions of our articles of incorporation and bylaws regarding the election and removal of directors;
    
	 	 	 
	 	●

	a prohibition on stockholder
    action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
    
	 	 	 
	 	●

	the requirement that
    a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer,
    the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal
    or to take action, including the removal of directors; and 
	 	 	 
	 	●

	advance notice procedures
    that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted
    upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of
    proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

 

These
provisions could inhibit or prevent possible transactions that some stockholders may consider attractive.

 

NASDAQ
Capital Market

 

Our
Common Stock and Public Warrants are currently traded on the NASDAQ Capital Market under the symbols “SGLB” and “SGLBW”
respectively.

 

Nevada
Anti-Takeover Law and Charter and Bylaws Provisions

 

NRS
sections 78.378 to 78.3793 provide state regulation over the acquisition of controlling interest in certain Nevada corporations
unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply.
This statute currently does not apply to our company because in order to be applicable, we would need to have a specified number
of Nevada residents as shareholders, and we would have to do business in Nevada directly or through an affiliate.

 

    	 	4Exhibit
10.15

 

December
2, 2019

 

Mark
Ruport

1729
Wood Avenue

Colorado
Springs, CO 80907

 

Re:
Terms of At-Will Employment

 

Dear
Mr. Ruport,

 

This
letter confirms the principal terms of our agreement, as set forth below, with respect to your at-will employment (“Employment”)
by Sigma Labs, Inc. (the “Company”), which shall be effective as of December 3, 2019 (the “Effective
Date”):

 

1.
Position; Reporting; Duties, Responsibilities and Authority; Principal Business Office; Board Membership: Effective as
the Effective Date, you shall serve as Executive Chairman of the Company and will report directly to the Board of Directors.

 

You
shall devote substantially all of your business time to the Company, and shall perform those services customary to your position
at a public company of a similar size as the Company and shall perform such other lawful duties that the Board of Directors of
the Company may reasonably assign to you from time to time. You shall at all times be subject to, observe and carry out such reasonable
employment- related rules, regulations and policies as the Company’s Board of Directors may from time to time establish
for the Company’s employees, including, without limitation, the Company’s Employee Handbook, Insider Trading Policy
and Code of Ethics and Business Conduct.

 

Without
restricting any requirement that you engage in reasonable business-related travel, you may work remotely from your home office,
provided that you make yourself readily accessible to the Company by telephone, via the Internet or other remote access, as you
deem reasonably necessary for the performance of your services hereunder, and provided, further, that the Company expects that
you will use reasonable efforts to perform your duties at the Company’s principal business office, which is presently located
at 3900 Paseo del Sol, Santa Fe, New Mexico 87507, every other week during the term of this Agreement for up to three to four
days per week, unless otherwise agreed by you and the Company.

 

For
as long as you serve as the Executive Chairman, you will serve on the Board of Directors of the Company.

 

2.
At-Will Employment: The Company has the right to terminate your Employment at any time, with or without prior notice, and
with or without cause and for any reason or for no specified reason. You have the right to terminate your Employment at any time,
with or without prior notice. You are employed by the Company “at will,” and this letter does not provide you with
any right to continue in the Employment of the Company for any minimum or specified period. Except as specifically provided in
this letter, the Company shall have no obligation to make any compensation, severance or other payments to you, or to provide
any other benefits to you, after the date of the termination of your Employment for any reason.

 

3.
Compensation:

 

(a) Base:
For services rendered hereunder, the Company shall pay to you an annual base salary (the “Base Salary”) of
$155,000, payable in regular installments in accordance with the Company’s customary payroll practices for employees.
If you are entitled to receive Base Salary for any period that is less than one calendar month, the Base Salary for such
period shall be computed by prorating the annual Base Salary over such period based upon the actual number of days therein.
The Base Salary shall not be subject to decrease but may be increased in the discretion of the Company’s Compensation
Committee based on annual or special case assessments of your performance and other factors. All payments shall be made in
accordance with the Company’s payroll practices. The Company may deduct and withhold from your compensation under this
agreement any amounts of money required to be deducted or withheld by the Company under any or all applicable local, state or
federal laws.

 

    	 

    	 

    

 

(b)
Benefits: During your Employment, you shall be entitled to receive all benefits under any and all deferred compensation
plans, retirement plans, life, disability, health, accident and other insurance programs, automobile allowances, and similar employee
benefit plans and programs, sick leave, vacation time and paid time off (if any) that the Company elects in its sole discretion
to provide from time to time to its other executive officers (collectively referred to herein as the “Benefits”).
However, we reserve the right to terminate, reduce or otherwise amend any or all of the Benefits from time to time to the extent
allowed by law, so long as such action applies generally to all of our executive officers. Except as otherwise required by applicable
law with respect to continued “COBRA” group health care coverage and except as expressly required by the terms of
the Company’s life, disability, health, accident and other insurance programs and similar employee benefit plans and programs,
your right to receive Benefits shall terminate upon the termination of your Employment for any reason. Subject to applicable terms
in the Company’s employee manual, you shall be entitled to vacation time of three weeks during each 12-months of the term
of this Agreement, and up to two weeks of discretionary sick, personal, or other personal needs, and eleven floating holidays
that you make take at the traditional national days or other days of your choice. You shall also be eligible to receive grants
of stock appreciation rights from time to time. However, the decision to grant any such stock appreciation rights, and the amount
and terms thereof, shall be in the sole and absolute discretion of the Compensation Committee.

 

(c)
Expense Reimbursement: The Company will reimburse you for ordinary and necessary expenses incurred in the performance of
your duties, provided that such expenses are reasonable and are accounted for in accordance with the Company’s usual policies.
Additionally, in light of your anticipated travel to the Company’s principal business office, as set forth in Section 1
above, you shall be entitled to an expense allowance of up to $1,200 per month to be applied to your housing in Santa Fe, subject
to promptly providing the Company with applicable receipts.

 

(d)
Options: Subject to your entering into the Company’s standard-form nonqualified stock option agreement, effective
as of the effective date of the approval of the Compensation Committee (the “Grant Date”), the Company shall
grant you (1) a non-qualified stock option (“Option A”) to purchase up to 100,000 shares of common stock of
the Company, which will have an exercise price equal to the closing price of the Company’s common stock on the Grant Date,
and will vest and become exercisable in full on the first month’s anniversary of the Grant Date, and (2) a non-qualified
stock option (“Option B,” and together with Option A, the “Options”) to purchase up to 400,000
shares of common stock of the Company, which will have an exercise price equal to the closing price of the Company’s common
stock on the Grant Date, and will vest and become exercisable in equal (as closely as possible) monthly installments over three
years from the Grant Date, provided, in each case, that you remain an employee of the Company through such vesting date.

 

    	 

    	 

    

 

The
Options shall expire on the day before the fifth anniversary of the Grant Date, unless the Options shall have been terminated
prior to that date in accordance with the provisions of the Company’s standard-form nonqualified stock option agreement.
Notwithstanding anything to the contrary, (x) upon the occurrence of a Change of Control, any unvested portion of the Options
held by you as of the date of such Change of Control shall immediately and automatically vest (provided, however, that, the Options
may be assumed or, in the discretion of the Board of Directors, an equivalent option may be substituted by an applicable successor
corporation or any subsidiary of the successor corporation in connection with a Change of Control), and (y) in the event that
the Board of Directors determines that you are unable to perform your duties as the Company’s Executive Chairman due to
an accident, illness or other event or condition which physically or mentally incapacitates you for a period of 45 consecutive
days (“Disability”), if you cease to be employed by the Company as a result of a Disability, the Options will
continue to vest and remain exercisable for the 5-year term of the Options in accordance with the terms of the option agreements.
As used herein, the term “Change of Control” shall mean (a) a merger or consolidation of the Company with or
into another corporation or entity (other than a merger with a wholly-owned subsidiary), whereby any Person or Persons acting
in concert acquire(s) more than 50% of the outstanding stock of the Company, (b) a sale of all or substantially all of the assets
of the Company, or (c) a purchase or other acquisition of more than 50% of the outstanding stock of the Company by one Person
or by more than one Person acting in concert. As used herein, the term “Person” shall mean an individual, partnership,
limited liability company, trust, estate, association, corporation, or any other legal entity.

 

In
the event of any stock split, reverse stock split or stock dividend after the date hereof, the number of shares of the Company’s
common stock underlying the Options, and the exercise price of the Options shall be appropriately adjusted for any such stock
split, reverse stock split or stock dividend.

 

(e)
Discretionary Bonus: During the term of your employment, you shall be eligible to receive one or more bonuses (“Discretionary
Bonuses”) relating to each fiscal year in recognition of your achievement of individual and Company goals established by the
Board of Directors from time to time. However, the decision to provide any Discretionary Bonuses and the amount and terms of any
Discretionary Bonuses, including the payment of cash, the issuance of equity in the Company, or a combination of both, shall be
in the sole and absolute discretion of the Board of Directors.

 

4.
Confidential Information. You shall at no time, either during your Employment or after the termination of your Employment
for any reason, use or disclose to any person, directly or indirectly, any confidential or proprietary information concerning
the business of the Company, including, without limitation, any business secret, trade secret, financial information, software,
internal procedure, business plan, marketing plan, pricing strategy or policy or customer list, except to the extent that such
use or disclosure is (1) necessary to the performance of your Employment during the period that you are so employed, (2) required
by an order of a court of competent jurisdiction, or (3) authorized in writing by the Company’s Board of Directors. The
prohibition that is contained in the preceding sentence shall not apply to any information that is or becomes generally available
to the public other than through a disclosure by you or by a person acting in concert with you. Within five days after the termination
of your Employment, you shall return to the Company all memoranda, notes and other documents in your possession or control that
relate to the confidential information of the Company. Upon the Company’s request, you agree to execute and deliver to the
Company any form of confidentiality agreement that the Company requires generally from its employees.

 

5.
Company Property: You agree that all designs, lists, books, files, reports, correspondence, computer databases and files,
records, supplies, services, computers, postage, telephones and other property and materials (“Company Materials”)
used by, prepared for or by, or made available to you while you are employed with the Company, shall be and shall remain the property
of the Company. Upon termination of your employment with the Company, all Company Materials shall be returned immediately to the
Company, and you shall not make or retain any copies thereof.

 

    	 

    	 

    

 

6.
Inventions/Work Product:

 

(a)
Work Product: You acknowledge and agrees that all writings, works of authorship, technology, inventions, discoveries, ideas
and other work product of any nature whatsoever that are created, prepared, produced, authored, edited, amended, conceived or
reduced to practice by you individually or jointly with others during the period of your Employment by the Company and relating
in any way to the business or contemplated business, research or development of the Company (regardless of when or where the Work
Product is prepared or whose equipment or other resources is used in preparing the same) and all printed, physical and electronic
copies, all improvements, rights and claims related to the foregoing, and other tangible embodiments thereof (collectively, “Work
Product”), as well as any and all rights in and to copyrights, trade secrets, trademarks (and related goodwill), patents
and other intellectual property rights therein arising in any jurisdiction throughout the world and all related rights of priority
under international conventions with respect thereto, including all pending and future applications and registrations therefor,
and continuations, divisions, continuations-in-part, reissues, extensions and renewals thereof (collectively, “Intellectual
Property Rights”), shall be the sole and exclusive property of the Company.

 

(b)
Work Made for Hire; Assignment: You acknowledge that, by reason of being employed by the Company at the relevant times,
to the extent permitted by law, all of the Work Product consisting of copyrightable subject matter is “work made for hire”
as defined in 17 U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that the foregoing does
not apply, you hereby irrevocably assign to the Company, for no additional consideration, your entire right, title and interest
in and to all Work Product and Intellectual Property Rights therein, including the right to sue, counterclaim and recover for
all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding thereto throughout
the world. Nothing contained herein shall be construed to reduce or limit the Company’s rights, title or interest in any
Work Product or Intellectual Property Rights so as to be less in any respect than that the Company would have had in the absence
of this agreement.

 

(c)
Further Assurances; Power of Attorney. During and after your Employment, you agree to reasonably cooperate with the Company
to (1) apply for, obtain, perfect and transfer to the Company the Work Product as well as an Intellectual Property Right in the
Work Product in any jurisdiction in the world, and (2) maintain, protect and enforce the same, including, without limitation,
executing and delivering to the Company any and all applications, oaths, declarations, affidavits, waivers, assignments and other
documents and instruments as shall be requested by the Company. You hereby irrevocably grant the Company a power of attorney to
execute and deliver any such documents on your behalf in your name and to do all other lawfully permitted acts to transfer the
Work Product to the Company and further the transfer, issuance, prosecution and maintenance of all Intellectual Property Rights
therein, to the full extent permitted by law, if you do not promptly cooperate with the Company’s request (without limiting
the rights the Company shall have in such circumstances by operation of law). The power of attorney is coupled with an interest
and shall not be affected by your subsequent incapacity.

 

    	 

    	 

    

 

7.
Notices: Any notice, consent, request or other communications made or given in connection with this agreement shall be
in writing and shall be deemed to have been duly given when delivered or mailed by postage prepaid to those listed below at their
following respective addresses or at such other address as each may specify by notice to the other:

 

To
the Company:

 

John
Rice

Chief
Executive Officer

Sigma
Labs, Inc.

3900
Paseo del Sol

Santa
Fe, NM 87507

 

To
you:

 

Mark
Ruport

1729
Wood Avenue

Colorado
Springs, CO 80907

 

8.
Entire Agreement: This agreement (and any separate confidentiality agreements that may be entered into between the Company
and you) constitutes the entire agreement of the Company and you relating to the terms and conditions of your Employment and supersedes
all prior oral and written understandings and agreements relating to such subject matter.

 

9.
Amendment and Termination: This agreement may be amended or terminated only pursuant to a writing executed by an authorized
officer of the Company and you.

 

10.
Arbitration: Any dispute or controversy arising under this agreement relating to its interpretation or the breach hereof,
including the arbitrability of any such dispute or controversy (each, a “Disputed Matter”), shall be determined
and settled by arbitration in Santa Fe, New Mexico pursuant to the Rules of the American Arbitration Association in effect at
the time the Disputed Matter arises. Any award rendered herein shall be final and binding on each and all of the parties, and
judgment may be entered thereon in any court of competent jurisdiction. Notwithstanding the foregoing, the parties shall be entitled
to seek injunctive relief in any court of competent jurisdiction.

 

11.
Governing Law: This agreement shall be governed by and construed in accordance with Nevada law. In the event that any terms
or provisions of this agreement shall be held to be invalid or unenforceable, such invalidity or unenforceability shall not affect
the validity or enforceability of the remaining terms and provisions hereof. In the event of any judicial, arbitral or other proceeding
between the parties hereto with respect to the subject matter hereof, the prevailing party shall be entitled, in addition to all
other relief, to reasonable attorneys’ fees and expenses and court costs.

 

If
the foregoing terms are acceptable, please sign below and return this letter to me.

 

	Sigma
Labs, Inc.	 	Employee 
	 	 	 
	/s/
    John Rice	 	/s/
    Mark K. Ruport
	John
    Rice, President and Chief Executive Officer	 	Mark
    K. Ruport

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]